Webinar Overview
Characterizing therapeutic TIDES (peptides and oligonucleotides) is increasingly challenging due to their complex structures, dynamic behaviors, and evolving regulatory requirements. High-resolution structural insights are essential to ensure the safety, quality, and efficacy of these therapeutics.
Recent advancements in NMR technology—including ultra-high magnetic fields, innovative probe configurations, and advanced software algorithms—are transforming the confidence and efficiency of TIDES characterization. These innovations help researchers and manufacturers meet regulatory demands and ultimately improve patient outcomes.
Tuesday, 11 November 2025
12:15 AM EST
What to Expect
- An up-to-date overview of the TIDES market and regulatory landscape, including recent FDA and EMA guidelines.
- Insights into the analytical challenges of characterizing peptides and oligonucleotides, with a focus on critical quality attributes such as primary sequence, stereochemistry, higher-order structure, impurity profiling, and purity assessment.
- Real-world case studies demonstrating how cutting-edge NMR technology and automated software solutions accelerate and simplify the structural elucidation of complex TIDES.
- A look at the latest developments in automated NMR analysis, including machine learning-driven peak picking, assignment, and structure determination, reducing time and expertise required for high-confidence results.
- Practical examples of oligonucleotide stereochemistry analysis and advanced chemical profiling (ACP) for precise, quantitative characterization.
Key Learning Points
- Understand the Evolving TIDES Landscape:
Explore current trends in peptide and oligonucleotide therapeutics, including market growth, approval rates, and therapeutic areas. - Master Analytical Strategies:
Learn how advanced NMR, LC-MS, HPLC, and spectroscopy techniques address the most stringent regulatory requirements for TIDES characterization. - Accelerate Structure Elucidation:
Discover how automation and machine learning are revolutionizing NMR data analysis, enabling faster, more accurate assignments and structure determinations—even for non-experts.
Who Should Attend?
This webinar is designed for professionals involved in:
- Drug discovery, development, and manufacturing of peptides and oligonucleotides
- Analytical and structural characterization of biotherapeutics
- Regulatory affairs and quality assurance
- Academia and research institutions focused on protein chemistry and nucleic acid therapeutics
Speakers
Dr. Victor Beaumont
Strategic Market Development Specialist, Bruker BioSpin
Victor has studied and applied NMR techniques throughout his undergraduate studies at the University at Buffalo (Dr. Thomas Szyperski) and PhD program at Yale University (Dr. Patrick Loria). He later joined Pfizer as an NMR specialist for biotherapeutic structure characterization moving then to project management of analytical laboratory automation. His passion is in improving the quality of life and working efficiencies of society by facilitating and contributing high-quality scientific innovation focused on state-of-the-art NMR characterization of novel therapeutic modalities. At Bruker, he is dedicated to working with scientists in understanding the challenges and needs of the industry to expand NMR applications and technology.